In the US, pancreatic cancer is diagnosed around 57,000 times each year. Credit: Ed Uthman.

AngioDynamics has received approval from the US Food and Drug Administration (FDA) for an investigational device exemption (IDE) application of its NanoKnife System in the treatment of stage III pancreatic cancer.

The NanoKnife System is designed for surgical ablation of soft tissue. It uses low-energy electrical pulses to permanently open pores in target cell membranes, which leads to cell death.

Go deeper with GlobalData

Go deeper with GlobalData

The gold standard of business intelligence.

Find out more

Discover B2B Marketing That Performs

Combine business intelligence and editorial excellence to reach engaged professionals across 36 leading media platforms.

Find out more

In 2008, the FDA granted 510(k) clearance for the device. The latest lDE approval will enable AngioDynamics to initiate its DIRECT clinical study, which will evaluate the NanoKnife System in around 250 patients with stage III pancreatic cancer.

The study will involve a series of randomised controlled trials (RCT) in up to 15 clinical sites and real-world evidence, next-generation registry (RWE) at up to 30 centres.

“We are confident that our comprehensive approach, crafted through a constructive dialogue with the FDA, will generate meaningful data for clinicians.”

The primary endpoint of the study is overall survival (OS). The trial will work with a comprehensive data collection strategy to capture meaningful clinical information and support a regulatory indication for pancreatic cancer.

AngioDynamics president and CEO Jim Clemmer said: “We are confident that our comprehensive approach, crafted through a constructive dialogue with the FDA, will generate meaningful data for clinicians, patients, payors and other stakeholders who are equally committed to fighting this disease, and we are dedicated to the idea that the standard of care for this deadly disease can and should improve.”

GlobalData Strategic Intelligence

US Tariffs are shifting - will you react or anticipate?

Don’t let policy changes catch you off guard. Stay proactive with real-time data and expert analysis.

By GlobalData

The company is launching AngioDIRECT.com to enable patient enrolment into the DIRECT study. This platform will consist of information about pancreatic cancer and the study.

A physician locator will also be available on the platform to facilitate identification of study locations.

In the US, pancreatic cancer is diagnosed in around 57,000 people each year and leads to approximately 46,000 deaths.

Medical Device Network Excellence Awards - Nominations Closed

Nominations are now closed for the Medical Device Network Excellence Awards. A big thanks to all the organisations that entered – your response has been outstanding, showcasing exceptional innovation, leadership, and impact

Excellence in Action
SC MEDICA’s minimally invasive, radiation free spinal facet fixation system, FFX® is transforming spinal pain management and improving outcomes for surgeons and patients alike. Learn how SC MEDICA’s award-winning technology is redefining standards in facet joint pain treatment.

Discover the Impact